XML 30 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Financial Statements (Details) (USD $)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 24, 2012
Observations
Feb. 13, 2012
Observations
Feb. 10, 2012
Observations
Nov. 30, 2012
Nov. 30, 2011
Nov. 30, 2012
Segment
Nov. 30, 2011
May 31, 2012
Reporint_Unit
May 22, 2012
Consolidated Financial Statements (Textual) [Abstract]                  
Upfront payment       $ 15,105,000,000   $ 15,105,000,000      
Goodwill                 145,221,000
Number of reportable segments           1   2  
Number of observations 5 6 12            
Costs for quality call to action program           3,100,000      
Number of business days to provide response to FDA           15 days      
LC Bead sales         9,100,000   17,100,000    
Transaction and Severance costs related to Acquisition       1,700,000   3,900,000      
Estimated cost of project           3,400,000      
Costs incurred associated with closure of facility       279,000 587,000 616,000 883,000    
Core Technologies [Member]
                 
Consolidated Financial Statements (Textual) [Abstract]                  
Amortized estimated useful lives           15 years      
Vortex Medical [Member]
                 
Consolidated Financial Statements (Textual) [Abstract]                  
Total estimated purchase consideration       75,407,000   75,407,000      
Upfront payment       15,105,000   15,105,000      
Contingent consideration       60,302,000   60,302,000      
Goodwill       30,019,000   30,019,000      
Acquisition related costs           $ 325,000